CareX: Co-factoring for efficacy

Many nuclear receptors are targets for diabetes and other metabolic indications, with marketed compounds validating them. But such receptors can recruit and form a complex with more than one kind of co-factor to control DNA transcription. And new research indicates that the gene activated by a nuclear receptor depends, at least in part, on which co-factor the receptor recruits.

By tweaking small molecule ligands, CareX S.A. believes it can favor the recruitment of one co-factor over another to discover and develop drugs with fewer side effects to treat diabetes, obesity and cardiovascular diseases. ...